Comparing a strategy of sirolimus-eluting balloon treatment to drug-eluting stent implantation in de novo coronary lesions in all-comers: Design and rationale of the SELUTION DeNovo Trial - 14/03/23
, Florian Krackhardt, MD b, ⁎, Kris Bogaerts, PhD c, d, Philip Urban, MD e, Susanne Meis, BA f, Marie-Claude Morice, MD g, Simon Eccleshall, MD hRésumé |
Background |
Drug eluting stents (DES) are associated with a 2% to 4% annual rate of target lesion failure through 5-to-10-year follow-up. The presence of a metallic protheses is a trigger for neo-atherosclerosis and very late stent thrombosis. A “leave nothing behind” strategy using Drug Coated Balloons has been suggested; however, paclitaxel coated balloons are only recommended in selected indications. Recently a novel sirolimus eluting balloon, the SELUTION SLR TM 014 PTCA balloon (SEB) (M.A. MedAlliance SA, Nyon, Switzerland) has been developed.
Hypothesis |
A strategy of percutaneous coronary intervention (PCI) with SEB and provisional DES is non-inferior to a strategy of systematic DES on target vessel failure (TVF) at one and five years. If non-inferiority is met at 5 years, superiority will be tested.
Design |
SELUTION DeNovo is a multi-center international open-label randomized trial. Subjects meeting eligibility criteria are randomized 1:1 to treatment of all lesions with either SEB and provisional DES or systematic DES. Major inclusion criteria are PCI indicated for ≥1 lesion considered suitable for treatment by either SEB or DES and clinical presentation with chronic coronary syndrome, unstable angina or non-ST segment elevation myocardial infarction (NSTEMI). There is no limitation in the number of lesions to be treated. Target lesions diameters are between 2 and 5 mm. Major exclusion criteria are lesions in the left main artery, chronic total occlusions, ST segment elevation myocardial infarction and unstable non-ST segment elevation myocardial infarction. Three thousand three hundred twenty six patients will be included in 50 sites in Europe and Asia. TVF rates and their components will be determined at 30 days, 6 months and annually up to 5 years post-intervention. Among secondary endpoints, bleeding events, cost-effectiveness data and net clinical benefits will be assessed.
Summary |
SELUTION DeNovo trial is an open-label, multi-center international randomized trial comparing a strategy of PCI with SEB and provisional DES to a strategy of PCI with systematic DES on TVF at one and five years. Non-inferiority will be tested at one and five years. If non-inferiority is met at five years, superiority will be tested.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Plan
| Take home message: Rationale and design of the Selution De Novo trial which compares a strategy of percutaneous coronary intervention with drug eluting stents (DES) to a strategy of sirolimus eluting stents with DES |
|
| ClinicalTrials.gov Identifier: NCT04859985 |
Vol 258
P. 77-84 - avril 2023 Retour au numéro
Article précédent
- Design and pilot implementation for the BETTER CARE-HF trial: A pragmatic cluster-randomized controlled trial comparing two targeted approaches to ambulatory clinical decision support for cardiologists
- Amrita Mukhopadhyay, Harmony R. Reynolds, Yuhe Xia, Lawrence M. Phillips, Rod Aminian, Ruth-Ann Diah, Arielle R. Nagler, Adam Szerencsy, Archana Saxena, Leora I. Horwitz, Stuart D. Katz, Saul Blecker
- Prehospital treatment with zalunfiban (RUC-4) in patients with ST‐ elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial
- Sem A.O.F. Rikken, Abi Selvarajah, Renicus S. Hermanides, Barry S. Coller, C. Michael Gibson, Christopher B. Granger, Frédéric Lapostolle, Sonja Postma, Henri van de Wetering, Risco C.W. van Vliet, Gilles Montalescot, Jurriën M. ten Berg, Arnoud W.J. van ’t Hof, CELEBRATE investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?